AUTHOR=Yadav Surekha , Kim Sarasa T. , Tuchayi Abuzar Moradi , Jiang Fei , Morley Amanda , Saelee Rachelle , Wang Yingbing , Juarez Roxanna , Lawnh-Heath Courtney , Koshkin Vadim S. , Hope Thomas A. 

TITLE=Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1382582

DOI=10.3389/fonc.2024.1382582

ISSN=2234-943X

ABSTRACT=<sec><title>Purpose</title><p><sup>68</sup>Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for <sup>177</sup>Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-DCFPyL.</p></sec><sec><title>Methods</title><p>We retrospectively evaluated 80 patients undergoing PSMA RLT, who had pretreatment imaging using either <sup>68</sup>Ga-PSMA-11 or <sup>18</sup>F-DCFPyL. For both groups, we compared the biodistribution and lesion uptake and the PSA response to treatment.</p></sec><sec><title>Results</title><p>Both agents had comparable biodistribution. Patients initially imaged with <sup>18</sup>F-DCFPyL had a higher PSA response (66% vs. 42%), and more patients had a PSA50 response (72% vs. 43%) compared to patients imaged with <sup>68</sup>Ga-PSMA-11.</p></sec><sec><title>Conclusion</title><p><sup>18</sup>F-DCFPyL and <sup>68</sup>Ga-PSMA-11 had comparable biodistribution and lesion uptake. Patients imaged with <sup>18</sup>F-DCFPyL demonstrated clinical benefit to PSMA RLT comparable to those imaged with <sup>68</sup>Ga-PSMA-11, and either agent can be used for screening patients.</p></sec>